SecBot SecBot
SECBOTREPLAY Home › Report › ASND

ASND · Ascendis Pharma reported Week 104 data from the pivotal ApproaCH Trial…

Ascendis Pharma · PRESS-RELEASE filed Jun 30, 2026 at 08:30 ET

At the news

BULLISHIMPACT 5/10

PRESS-RELEASE filed Jun 30, 2026 at 08:30 ET

Ascendis Pharma reported Week 104 data from the pivotal ApproaCH Trial showing continued improvement in lower extremity alignment (tibial-femoral angle) in children with achondroplasia treated with once-weekly TransCon CNP (navepegritide). The data reinforces the drug's safety and efficacy profile, but TransCon CNP (YUVIWEL) was already FDA-approved in February 2026, making this an incremental positive rather than a binary catalyst.

  • TransCon CNP-treated children showed a mean TFA improvement of -2.2 degrees over two years (baseline 9.1° to 6.9° at Week 104).
  • In children with preexisting genu varum (baseline TFA ≥5°), mean TFA improved -3.8 degrees over two years (13.4° to 9.6°).
  • TransCon CNP was generally well tolerated with no treatment discontinuations and no acceleration of bone age.
  • YUVIWEL (TransCon CNP) received FDA approval in February 2026 for pediatric achondroplasia; EMA decision on Marketing Authorisation Application expected Q4 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access